Brokerage: PhillipCap | Rating: Maintain Sell | Target: Cut to Rs 1,000
The global research firm said that the target includes value of special dividend of Rs 28 per share & net cash of Rs 211 per share. The stock is a long term negative as business opportunity shrinks for the listed company, it said, adding that mobility and mechanical drives business sale.
Brokerage: Deutsche Bank | Rating: Maintain Sell | Target: Rs 1,030
Deutsche Bank said that mobility separated just before the potential uptick. Meanwhile, it said that the stock is expensive on September FY19e P/E & EV/EBITDA Of 38.4x & 23.4x respectively. Valuations are steep for 26% PAT CAGR forecast over FY17-20.
Brokerage: Jefferies | Rating: Buy | Target: Rs 145
Jefferies said that acquisition of minority stake (26%) in Equirus Capital augurs well. It observed that synergies lie in broadening product offerings to corporate & SME clients. Going forward, steady loan growth, & improvement in operating efficiency should increase profitability.
Brokerage: Motilal Oswal | Rating: Buy | Target: Rs 1,840
Motilal Oswal said that growth ingredients were in place. Rejigged strategies have started yielding results in Asia. Further, the company expects dermatology business to recover over the next 9-12 months. It also observed that the company is on track to outperform industry in other key therapies as well. It expects minimal regulatory hurdles over the medium-term for the US market.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
